About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
BPMC - Blueprint Medicines ...| Previous Close | $95.95 | Open | $97.06 |
| Volume | 292.8K | Market Cap | 5.561B |
| Yield | Last Dividend |
| Blueprint Medicines to Showcase Scientif... | 03/10/21 |
| CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new data for multiple... | |
| Blueprint Medicines Announces EMA Valida... | 03/03/21 |
| CAMBRIDGE, Mass., March 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Medicines Agency (EMA... | |
| Robert W. Baird Stick to Their Buy Ratin... | 02/19/21 |
| Robert W. Baird Stick to Their Buy Rating for Blueprint Medicines | |
| Blueprint Medicines Reports Fourth Quart... | 02/17/21 |
| CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business... | |
| Blueprint Medicines Factors Likely to Ha... | 02/16/21 |
| Blueprint Medicines announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Blueprint Medicines to Report Fourth Qua... | 02/10/21 |
| CAMBRIDGE, Mass., Feb. 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically def... | |
| Blueprint Medicines Announces Inducement... | 02/05/21 |
| CAMBRIDGE, Mass., Feb. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defi... | |
| Blueprint Medicines Announces R&D Leader... | 01/11/21 |
| CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company'... | |
| Blueprint Medicines Submits Supplemental... | 12/17/20 |
| CAMBRIDGE, Mass., Dec. 17, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically def... | |
| Blueprint Medicines Data Presented at 62... | 12/07/20 |
| CAMBRIDGE, Mass., Dec. 7, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defi... | |
| The Daily Biotech Pulse: Pfizer-BioNTech... | 12/02/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 1) AbbV... | |
| Blueprint Medicines To Present Broad Ran... | 11/23/20 |
| CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically def... | |
| Earnings Scheduled For October 29, 2020 | 10/29/20 |
| Companies Reporting Before The Bell ??? PG&E (NYSE: PCG ) is likely to report quarterly earnings at $0.27 per share on revenue of $4.72 billion. ??? S... | |
| Analysts Expect Blueprint Medicines Corp... | 10/24/20 |
| Equities research analysts expect that Blueprint Medicines Corp (NASDAQ:BPMC) will announce sales of $565.91 million for the current fiscal quarter, a... | |
| Blueprint Medicines to Report Third Quar... | 10/22/20 |
| CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically def... | |
| Kate Haviland Sells 13,334 Shares of Blu... | 10/21/20 |
| Blueprint Medicines Corp (NASDAQ:BPMC) COO Kate Haviland sold 13,334 shares of the stock in a transaction that occurred on Friday, October 16th. The s... | |
| The Daily Biotech Pulse: Prothena Progre... | 10/21/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Ail... | |
| Blueprint Medicines Corp (NASDAQ:BPMC) C... | 10/20/20 |
| Blueprint Medicines Corp (NASDAQ:BPMC) COO Kate Haviland sold 13,334 shares of Blueprint Medicines stock in a transaction on Friday, October 16th. The... | |
| Insider Selling: Blueprint Medicines Cor... | 10/20/20 |
| Blueprint Medicines Corp (NASDAQ:BPMC) COO Kate Haviland sold 13,334 shares of the firm???s stock in a transaction dated Friday, October 16th. The sto... | |
| Blueprint Medicines (NASDAQ:BPMC) Sets N... | 10/19/20 |
| Blueprint Medicines Corp (NASDAQ:BPMC)???s share price hit a new 52-week high during trading on Monday after Raymond James raised their price target o... | |
| The Daily Biotech Pulse: Vertex Pulls Pl... | 10/15/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14) 10X... | |
| The Daily Biotech Pulse: J&J Pauses Coro... | 10/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X... | |
| The Daily Biotech Pulse: Gilead, Lilly C... | 10/08/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7) 10X ... | |
| The Daily Biotech Pulse: Bristol-Myers S... | 10/07/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) 10X ... | |
| The Daily Biotech Pulse: Pfizer, BioNTec... | 10/06/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) 10X ... | |
| The Daily Biotech Pulse: Amag Spikes On ... | 10/01/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Ac... | |
| The Daily Biotech Pulse: Eton Snags Seco... | 09/30/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Ac... | |
| Blueprint Medicines Reports ARROW Trial ... | 09/20/20 |
| CAMBRIDGE, Mass., Sept. 20, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically de... | |
| Blueprint Medicines Presents Foundationa... | 09/17/20 |
| CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically de... | |
| Blueprint Medicines to Present at 18th A... | 09/09/20 |
| CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defi... | |
| Strong Buy rating | 04/13/21 |
| Wedbush maintains Outperform rating and raises Price Target from $119.00 to $136.00 | |
| Hold rating | 03/31/21 |
| Credit Suisse initiates coverage with Neutral rating and announces Price Target of $100.00 | |
| Hold rating | 02/18/21 |
| Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $112.00 to $105.00 | |
| Buy rating | 02/18/21 |
| Barclays maintains Buy rating and raises Price Target from $90.00 to $95.00 | |
| Date | 2021-02-17 (BMO) | Est. (EPS/Rev.) | ($1.62)/ 29.24M |
| Actual (EPS/Rev.) | $-1.53/ $34.11 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Grinding For Green (Annual) | The Grim Contango | 100.00 % | Subscribe |
| Algo Options (2 weeks) | The Grim Contango | 84.00 % | Subscribe |
| 2% Milking (1 Month) | The Grim Contango | 83.00 % | Subscribe |
| 10 Picks Every Day (90 Days) | The Grim Contango | 78.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
